Evidence map›Paper›PMID 41789570›Full record

ArticleJournal of the American Chemical Society2026

NIR-II Nanomedicine Engineered CAR-NK Cells for Precision Navigation and Potentiating Lung Cancer Immunotherapy by Remodeling Tumor Microenvironment.

Yeneng Dai, Qihang Ding, Ze Chen, Guanda Jiao, Yiqi Yang, Shengyu Fu, Ziyi Yang, Xiaoxi Liu, Kun Qian, Zhen Cheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yeneng DaiCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Qihang DingDepartment of Chemistry, Korea University, Seoul 02841, Korea.ORCID 0000-0002-2665-9036
Ze ChenCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Guanda JiaoCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Yiqi YangCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Shengyu FuCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Ziyi YangCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Xiaoxi LiuCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Kun QianState Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhen ChengState Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.ORCID 0000-0001-8177-9463
Dongliang LengCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.
Qi ZhaoCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the prominent success against hematologic malignancies in clinical settings, chimeric antigen receptor NK (CAR-NK) cell immunotherapy is still hindered in lung cancer tumors owing to insufficient infiltration and poor immune activation induced by the immunosuppressive tumor microenvironment (TME). Herein, a nanoengineered CAR-NK biohybrid (CK-PSI) was constructed by conjugating nanomedicine (PSI NPs) containing a near-infrared II (NIR-II) polymer and a specific small-molecule inhibitor of Smad3 (SIS3) to the surface of metabolic glycan-engineered CAR-NK cells via a bioorthogonal reaction. Anti-B7H3 CAR modification on cell vectors offers selectively targeted delivery of hitchhiking NIR-II nanomedicine into lung cancer tumors, simultaneously enabling real-time tracking of CAR-NK cells and precise localization of deep-seated tumors through NIR-II fluorescence imaging. NIR-II excitation mild photothermal therapy not only destroys tumor cells by thermal ablation but also promotes the infiltration and penetration of CK-PSI through the rupture of physical barriers within tumor tissues. More importantly, the

Indexed as

ImmunotherapyKiller Cells, NaturalLung NeoplasmsNanomedicineReceptors, Chimeric AntigenTumor MicroenvironmentAnimalsHumansInfrared RaysMiceSmad3 ProteinReceptors, Chimeric AntigenSmad3 Protein

Identifiers

PMID41789570
PMCPMC13003482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.